Results 171 to 178 of about 11,363 (178)

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Lancet, The, 2015
Bryan Williams, Thomas Mac Lennan MacDonald, Steve V Morant   +2 more
exaly  

Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project)

Lancet, The, 2017
Jiapeng Lu, Yuan Lu, Xinyue Li
exaly  

Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial

Lancet, The, 2010
Richard J Mcmanus, Jonathan Mant, Billingsley Kaambwa   +2 more
exaly  

Sodium sensitivity and cardiovascular events in patients with essential hypertension

Lancet, The, 1997
Takashi Uzu
exaly  

Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis

Lancet, The, 2005
Bo Carlberg
exaly  

Clinical features of paediatric pulmonary hypertension: a registry study

Lancet, The, 2012
Rolf M F Berger, Maurice Beghetti, Tilman Humpl   +2 more
exaly  

A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension

Lancet, The, 2016
Michael Hecht Olsen, Sonia Y Angell, Pierre Boutouyrie   +2 more
exaly  

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

Lancet, The, 1991
exaly